Leptomeningeal metastases in non-small-cell lung cancer

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Leptomeningeal metastasis is a complication of advanced non-small-cell lung cancer (NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are based on neurological, radiographic, and cerebrospinal fluid findings. Substantial progress has been made in several key aspects of management of leptomeningeal metastasis, including improved characterisation of the genetic profiles, generation of clinically relevant animal models, advances in cerebrospinal fluid liquid biopsy with improved cytology and genotyping analysis, and the development of therapeutic agents with greater CNS penetration. This Review discusses cumulative data on multiple treatment modalities with a particular focus on recent advances in molecularly targeted therapies in subtypes of patients with leptomeningeal metastasis from NSCLC. Future research is needed to further understand the biology of leptomeningeal metastasis and the mechanisms of resistance to treatment.

Original languageEnglish (US)
Pages (from-to)e43-e55
JournalThe Lancet Oncology
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Cerebrospinal Fluid
Therapeutics
Cell Biology
Animal Models
Biopsy

ASJC Scopus subject areas

  • Oncology

Cite this

Leptomeningeal metastases in non-small-cell lung cancer. / Cheng, Haiying; Perez-Soler, Roman.

In: The Lancet Oncology, Vol. 19, No. 1, 01.01.2018, p. e43-e55.

Research output: Contribution to journalReview article

@article{9c79172c6426432295006edf4ee92485,
title = "Leptomeningeal metastases in non-small-cell lung cancer",
abstract = "Leptomeningeal metastasis is a complication of advanced non-small-cell lung cancer (NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are based on neurological, radiographic, and cerebrospinal fluid findings. Substantial progress has been made in several key aspects of management of leptomeningeal metastasis, including improved characterisation of the genetic profiles, generation of clinically relevant animal models, advances in cerebrospinal fluid liquid biopsy with improved cytology and genotyping analysis, and the development of therapeutic agents with greater CNS penetration. This Review discusses cumulative data on multiple treatment modalities with a particular focus on recent advances in molecularly targeted therapies in subtypes of patients with leptomeningeal metastasis from NSCLC. Future research is needed to further understand the biology of leptomeningeal metastasis and the mechanisms of resistance to treatment.",
author = "Haiying Cheng and Roman Perez-Soler",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S1470-2045(17)30689-7",
language = "English (US)",
volume = "19",
pages = "e43--e55",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Leptomeningeal metastases in non-small-cell lung cancer

AU - Cheng, Haiying

AU - Perez-Soler, Roman

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Leptomeningeal metastasis is a complication of advanced non-small-cell lung cancer (NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are based on neurological, radiographic, and cerebrospinal fluid findings. Substantial progress has been made in several key aspects of management of leptomeningeal metastasis, including improved characterisation of the genetic profiles, generation of clinically relevant animal models, advances in cerebrospinal fluid liquid biopsy with improved cytology and genotyping analysis, and the development of therapeutic agents with greater CNS penetration. This Review discusses cumulative data on multiple treatment modalities with a particular focus on recent advances in molecularly targeted therapies in subtypes of patients with leptomeningeal metastasis from NSCLC. Future research is needed to further understand the biology of leptomeningeal metastasis and the mechanisms of resistance to treatment.

AB - Leptomeningeal metastasis is a complication of advanced non-small-cell lung cancer (NSCLC). Diagnosis and monitoring of leptomeningeal metastasis are challenging, and are based on neurological, radiographic, and cerebrospinal fluid findings. Substantial progress has been made in several key aspects of management of leptomeningeal metastasis, including improved characterisation of the genetic profiles, generation of clinically relevant animal models, advances in cerebrospinal fluid liquid biopsy with improved cytology and genotyping analysis, and the development of therapeutic agents with greater CNS penetration. This Review discusses cumulative data on multiple treatment modalities with a particular focus on recent advances in molecularly targeted therapies in subtypes of patients with leptomeningeal metastasis from NSCLC. Future research is needed to further understand the biology of leptomeningeal metastasis and the mechanisms of resistance to treatment.

UR - http://www.scopus.com/inward/record.url?scp=85039746374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039746374&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(17)30689-7

DO - 10.1016/S1470-2045(17)30689-7

M3 - Review article

VL - 19

SP - e43-e55

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -